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drug-related problems (DRPs) among older adults prescribed multiple medications.
Methods: This prospective case-series intervention study was conducted at the outpatient
department of the National Taiwan University Hospital and its BeiHu Branch. Older adults
(65 years) who either had been prescribed 8 chronic medications (drugs prescribed for
28 days) or had visited 3 different physicians during the 3-month screening period were
enrolled (N Z 193). DRPs were identified after baseline assessments from a team of geriatri-
cians and pharmacists. Prescribers were contacted with proposed interventions to be adminis-
tered within 12 weeks. Problem-solving rates (PSRs) at both Week 12 and Week 24 visits were
recorded. Stepwise multivariate logistic regression was applied to identify correlates of having
at least one unsolved DRP at 24 weeks. Participants (NZ 139) who completed four visits to the
MSRCs were analyzed.
Results: The mean age was 75.6  6.1 years and 56% of them were men. The mean chronic
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Medication safety review clinicsdTaiwan 107The PSR was 76% at Week 12 and 87% at Week 24. Thirty-two patients (22%) had at least one
unsolved DRP. Correlates of the unsolved DRP included a higher geriatric depression scale,
a higher chronic medication per patient, and a higher DRP per patient. The mean chronic medi-
cation per patient (9.0 vs. 8.6, p < 0.05) decreased, and the number of participants rating
good or better health status improved from 22% to 38% in 24 weeks (p < 0.001). Participants
were highly satisfied (96% at all times) with the service.
Conclusion: DRPs were common in geriatric outpatients taking multiple medications and most
were solved with appropriate interventions. The MSRC service may improve prescription
quality in Taiwan if widely available.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Polypharmacy has been a major concern in Taiwan, with
one-third of frail elders being prescribed more than five
medications for more than 180 days in 1 year.1 Poly-
pharmacy makes older Taiwanese adults highly susceptible
to drug-related problems (DRPs). DRP is defined as “an
event or circumstance involving drug therapy that actually
or potentially interferes with desired health outcomes.”2
There are many classification systems for DRP designed to
be applied in clinical practice. Pharmaceutical Care
Network Europe (PCNE) classification was considered an
optimal system based on five major requirements.3
There is a lack of medical review service in Taiwan to
detect and solve DRPs among older adults.4 Communication
between pharmacists and prescribers can be improved by
including geriatricians with a strong medication review
training background.5 Therefore, a “medication safety
review clinic” (MSRC) established under collaborative efforts
between geriatricians and clinical pharmacists is probably
a more ideal model in Taiwan. The purpose of this study is to
measure the effectiveness of MSRC and provide suggestions
for implementation of similar services in Taiwan.Patients and methods
Design of MSRCs
Our research on MSRCs was performed at the outpatient
departments of the National Taiwan University Hospital
(NTUH) and its affiliated community hospital, its BeiHu
Branch. This work was supported by the Taiwan Department
of Health grant “Medication Safety Review Clinic in
Taiwanese Elders” and was approved by the institutional
review board at the NTUH in October 2007.
The clinic opened weekly at each participating hospital.
For each clinic session, one to two research assistants, one
clinical pharmacist, and one geriatrician were responsible
for collecting clinical and drug information, performing
assessments, formulating care plans, and monitoring
outcomes during the 24-week study period.
Each participant visited the clinic four times, including
initial, 3rd week, 12th week, and 24th week visit. Informed
consents were obtained at the baseline visit (with roughly
1-hour assessment). In-depth comprehensive geriatric
assessments, including physical, psychological, andfunctional status, were performed by history taking, phys-
ical examination, and assessments with special instruments
(detail described elsewhere).6 Medication reviews were
also performed to identify DRPs by collaboration of one
geriatrician and one clinical pharmacist, using the instru-
ments described later. Interventions were proposed by the
research team to the prescriber and/or patient. For
example, if the problem is poor adherence, the team
confirmed the indication and reinforced the importance of
medication adherence to the patient. The clinic was
designed to coordinate but not to substitute the original
care. Prescribers (NZ 139) were called by the geriatricians
in the research team to create mutually agreed interven-
tions to be presented to participants at the 15-minute
Week-3 visits. Nearly 10% (N Z 15) of the prescribers
were not affiliated with the NTUH healthcare system.
Participants were expected to see their prescribers at least
once in 12 weeks because of the National Health Insurance
(NHI) regulations. Unless immediate action was necessary
to protect patient safety, all drug-level interventions were
implemented at the next scheduled visit by the prescriber,
with reminder notes attached to the medical records by the
research team. For non-NTUH system prescribers, reminder
notes were mailed or faxed to their offices. The Week-12
visit also took about 15 minutes to determine the initial
problem-solving rate (PSR) and to identify new problems
based on the interval clinical condition and medication
changes. Prescribers were contacted again for new or
unsolved DRPs. The final PSR was determined at the 40-
minute Week-24 visits. Some standardized geriatric
assessments performed at baseline visits were repeated to
evaluate interval changes (Fig. 1). Overall, this study was
designed as a prospective case-series intervention to detect
and solve DRPs.Participants
Our target population was geriatric (aged 65 years) outpa-
tientswhoeitherhadbeenprescribed8 chronicmedications
(drugs prescribed for 28 days) or had visited 3 different
physicians at the two participating hospitals in 3 months prior
to October 2007. The second criterion was selected because
past research showed that multiple prescribers significantly
increased the risk of polypharmacy.7e9
Twenty-eight core physicians were invited to refer their
patients to the MSRCs. Of the 668 patients whose contact
phone numbers were provided to the research team, 285
Initial visits 
60 min
Enrollment criteria: 
1. Age ≥65 y 
2. One of the prescribers belongs to the “core physician” group 
3. From Aug 2007 to Oct 2007, either 
A. Prescribed with ≥8 chronic medications (prescription ≥28 d) or 
B. Visited ≥3 different prescribers 
Comprehensive medical and medication 
review to identify DRPs by the research team 
with geriatricians, pharmacists, and research 
assistants
Making suggestions and providing patients 
with medication safety cards
Reviewing medication and clinical condition 
changes after initial visits 
Following outcomes of interventions on 
DRPs identified in initial visits 
Identifying new DRPs and contacting 
prescribers when appropriate  
Week-12 visit 
15 min
Week-3 visit 
15 min
Geriatricians contacted prescribers to discuss DRPs and develop mutually 
agreed upon interventions 
N = 193
N = 167
N = 149
Following outcomes of interventions on 
DRPs identified in initial and Week-12 visits 
Repeating   assessments of initial visit to 
detect changes in function, cognition, 
mood, geriatric syndromes, and healthcare 
resource utilizations 
Week-24 Visit 
40 min
N = 139
Instrument used to assess DRPs: 
Pharmaceutical Care Network Europe classification for drug-related 
problems, version 5.01  
N = 668 referred with contact numbers 
■
■
■
■
■
Figure 1 Study flow of the medication safety review clinics for Taiwanese elders. DRP Z drug-related problem.
108 D.-C. Chan et al.(43%) were not reachable within three attempts, 190 (28%)
declined the service, and 193 (29%) were enrolled. Among
the 193 participants, 167 (87%) returned for the Week-3
visits, 149 (77%) returned for the Week-12 assessments, and
139 (72%) completed the Week-24 visits and were included
in the final analysis (Fig. 1). All participants who dropped
out from the study were contacted at least three times to
schedule their follow-up visits to the MSRC. However, they
still declined the service.
Medication evaluation process and instruments
The “chronic medication” concept was unique to the study.
These medications were intended to be taken regularly to
treat chronic conditions and were the targets of review(described in detail elsewhere).6 Information was collected
for all drugs prescribed in the past 3 months. Besides
medications, clinical data including demographics, detailed
medical histories and physical examination results, geri-
atric syndromes (e.g., fall and depression), physical func-
tioning (e.g., Nagi index),10 patient satisfactions, and
healthcare resource utilization were also collected by the
research team.
DRPs were identified after considering indication,
dosage, adherence, interactions (using the MICOMEDEX
Healthcare Series Software), adverse reactions, and
therapeutic effects of each medication or diet supple-
ment. NTUH-modified 2003 Beers criteria6,11 were also
used to identify potentially inappropriate medications.
The PCNE classification for drug-related problems,
Medication safety review clinicsdTaiwan 109version 5.1,2 was used to record problems. In this study,
every participant took multiple medications. Each medi-
cation might have led to more than one problem. Each
problem was recorded separately and reported in the
problem-level results. At an individual level, the
percentage of participants having at least one DRP was
reported.
Each problem was assigned to one of the six problem
domains, with up to three causes selected and up to three
interventions proposed. One outcome had to be specified
later to determine the response to interventions. Four
domains of possible outcomes were available:
O0doutcome not known, O1dproblem totally solved,
O2dproblem partially solved, and O3dproblem not solved.
Assignments and coding of problems, causes, interventions,
and outcomes were derived from consensus among a team
of geriatricians and pharmacists.Outcomes
Since one participant might have multiple problems,
problem- and individual-level outcomes were defined
separately. At the problem level, PSR was defined as the
summation of problems totally (O1) or partially (O2) solved,
divided by the total numbers of DRPs. The prespecified
cutoff point of 75% was used.
At the individual level, patients who had at least one
unsolved DRP were identified. Other individual-level
outcomes included changes in the number of total
medications, changes in physical functioning, selected
geriatric syndromes, healthcare resources utilizations,Table 1 Baseline and 24-week follow-up characteristics among
Total N Z 139 B
Demographics
Age (y) 7
Sex (male) 7
Education (>9 y) 7
Health-related characteristics
Chronic condition per patient 9
Chronic medication per patient 9
Drug-related problem per patient 2
Having at least one drug-related problem (yes) 1
In general, would you say your health is (good or better) 3
Nagi index score (0e28) 2
Instrumental activities of daily living score (0e32) 3
Timed-up-and-go test (s) 1
Mini mental status examination score (0e30) 2
Geriatric depression scale-15 score (0e15) 1
Fall history in 6 mo (Yes) 1
Dizziness in 6 mo (Yes) 4
Healthcare utilization numbers in past 6 mo 5
Patient satisfaction-related characteristics
How do you rate your experience of the clinic? (satisfied)b 1
NA Z not applicable; SD Z standard deviation.*p < 0.05, **p < 0.00
a Number and percentage were reported for categorical variables,
b Patient satisfaction was collected at Week 3, not at the baselineand patient satisfactions between assessments at Weeks 1
and 24.
Statistical analysis
Data were analyzed using the Stata8 statistical package
(Stata, College Station, TX, USA). Individual- and problem-
level analyses were done separately. There were no missing
data on DRPs. Missing data for other participant charac-
teristics were <5%. Data were entered into the most
prevalent categories for categorical variables and mean
value for continuous variables. Differences between two
assessment time points at individual level were analyzed
using paired t test for continuous variables and McNemar’s
test with exact modification for categorical variables.
Stepwise multivariate logistic regression (MLR) analysis was
applied to identify baseline-independent correlates for
having at least one unsolved DRP at 24 weeks. There were
significant collinearity among chronic condition per
patient, chronic medication per patient, and DRP per
patient variables. Therefore, three different MLR models
were reported. Significant a was set at p < 0.05. All tests
were two tailed.
Compared with the patients retained in the final analysis
(NZ 139), those who lost to follow-up (NZ 54) were older
(77.8  6.4 vs. 75.6  6.1 years, pZ 0.027); had lower Nagi
index (23.5  4.6 vs. 25.4  3.7, p Z 0.003), lower
Instrumental Activity of Daily Living (IADL) scores
(27.6  6.1 vs. 30.0  3.7, p Z 0.001), and longer timed-
up-and-go seconds (13.7  5.1 vs. 11.6  4.4, p Z 0.005);
and were more likely to have at least one noncore
prescriber (74% vs. 58%, p Z 0.034).medication safety review clinic patients.
aseline, N (%) or mean  SDa 24 wk, N (%) or mean  SDa
5.6  6.1 NA
8 (56) NA
0 (50) NA
.0  2.6 NA
.0  3.1 8.6  3.1*
.1  1.5 NA
22 (88) NA
0 (22) 53 (38)**
5.4  3.7 24.9  3.7*
0.0  3.7 29.5  4.3*
1.6  4.4 12.7  7.1
7.5  3.6 27.1  4.2
.0  2.6 1.2  2.8
8 (13) 23 (17)
6 (33) 48 (34)
.1  3.3 4.9  3.2
34 (96) 134 (96)
1.
while mean and SD were reported for continuous variables.
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Baseline characteristics
Table 1 shows the baseline characteristics of the study
participants (N Z 139). As expected, the participants had
multiple chronic conditions (9.0  2.6) and used many
chronic medications (9.0  3.1). Eighty-eight percent had
at least one DRP at baseline with the mean DRP numbers of
2.1  1.5.
Only 22% of participants rated their general health
status as good or excellent, although participants had
relatively well-preserved physical and mental functions, as
shown by high Nagi Index scores and other standardized
assessments. Nearly all participants (96%) were satisfied
with the MSRC services.
Problem-level outcomes
At baseline, 297 DRPs were found for the 139 participants.
The top three problem categories were drugs not taken or
not administered (n Z 98, 33%), potential interaction
(n Z 35, 12%), and inappropriate duplication of drug
(n Z 34, 11%). At Weeks 12, 13 new DRPs were identified
(Table 2). At Week 12, the PSR was 76%. At Week 24, 87% of
the problems were solved (Table 2).
The P2 (drug choice) domain showed the lowest PSR at
both times (60% and 73%) (Table 2). However, there were
still significant variations within the domain. Prescribers
were more likely to agree with recommendations on inap-
propriate duplications of drugs (P2.3, 74% and 91%), rather
than with recommendations regarding drug indications
(P2.5, 50% and 63%; P2.6, 50% and 63%).
Among the 40 unsolved DRPs at Week 24, the top two
categories were “no clear indication for drug” (P2.5,
N Z 12), and “no drug but clear indication” (P2.6, N Z 7)
(Table 3). Antiplatelet agents were the most often omitted
drugs, as suggested by the research team (Table 3).
Individual-level outcomes
Among the 139 participants, 32 (22%) had at least one unre-
solved DRP. Specifically, one had three, six had two, and the
remaining 25 had one unsolved DRPs (Table 3). When chronic
condition per patient was included as a covariate, higher
geriatric depression scale (GDS)-15 score was associated
with having at least one unsolved DRP at 24 weeks (Table 4,
model 1). Having higher chronic medication per patient
(Table 4, model 2) and having higher DRP per patient (Table
4, model 3) were the only significant correlates of unsolved
DRPs in the other two models, respectively.
Most other individual-level outcomes did not change
over the 24-week period (Table 1). However, the
percentage of participants who rated their general health
as good or better increased from 22% to 38% in 24 weeks
(McNemar’s chi-square Z 11.76, p Z 0.001). The mean
number of chronic medications also decreased by 0.4
(paired t Z 2.014, p Z 0.046). Unexpectedly, we also
found a functional decline of 0.5 points in both the mean
Nagi index and the mean IADL scores (paired tZ 1.993 and
2.366, p Z 0.048 and 0.019, respectively).
Table 3 Classification of remaining unsolved DRPs.
Problem Medication Id
P1.1: side effect suffered (nonallergic) (N Z 3) Dicyclomine 1113
Doxazosin 2001
Felodipine 2019
P2.1: inappropriate drug (N Z 3) Chlorzoxazone þ paracetamol 1059
Ticlopidine 1050
Ticlopidine 1119
P2.3: inappropriate duplication of drug (N Z) Flunitrazepam 1017
Hydrotalcite 1028
Lorazepam 1039
P2.5: no clear indication for drug (N Z 12) Aminophylline 1123
Aminophylline 2001
Clonazepam 2028
Digoxin 1003
Digoxin 1008
Extract of ginkgo biloba 2055
Flupentixol þ melitracen 1033
Imipramine 2005
Pentoxifylline 1017
Pentoxifylline 1059
Piracetam 1015
Simethicone 2005
P2.6: no drug but clear indication (N Z 7) Antiplatelet agent 1049
Antiplatelet agent 1084
Antiplatelet agent 1092
Antiplatelet agent 2008
Antiplatelet agent 2022
Proton pump inhibitor 1034
Salmeterole/fluticasone 1017
P3.1: drug dose too low/not frequent enough (N Z 1) Trazodone 2032
P3.2: Drug dose too high/too frequent (N Z 1) Digoxin 1105
P4.1: Drug not taken/administered (N Z 4) Lorazepam 1112
Oxethazaine and polymigel 1071
Propranolol 1011
Trichlormethiazide 1011
P5.1: potential interaction (N Z 3) Amiodarone (vs. simvastatin) 1013
Digoxin (vs. thiazide) 2024
Etodolac (vs. clopidogrel) 1028
P6.5: other problem (specify) (N Z 3) Magnesium oxide 2027
Zopiclone 2050
Benzbromarone 2050
DRP Z drug-related problem; Id Z study identification number.
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Among geriatric outpatients taking multiple drugs, we
identified 88% participants with at least one DRP at our
MSRCs. With collaborative efforts, 87% of the problems
were solved. Correlates of having at least one unsolved DRP
included higher GDS-15 score, higher chronic medication
per patient, and higher DRP per patient. After interven-
tions, the number of prescribed chronic medication per
patient was decreased and the participants had better self-
reported health status. Participants were highly satisfied
with the service.
Given polypharmacy as a strong risk factor for
DRPs,7,8,12,13 it was not surprising that the prevalence andthe DRP per patient were high in the participants at our
MSRCs. Our study extended the knowledge that poly-
pharmacy is also an important determinant for unsolved
DRPs, which has not been studied extensively in the liter-
ature. The relationship between higher GDS and unsolved
DRPs could partially be explained by the fact that depres-
sion increased the risk of nonadherence to medication and
other medical management.14
Consistent with previous studies,15e19 prescribing physi-
cians and patients were generally receptive to our inter-
ventions. Most prescribers appreciated the MSRC services
especially when they did not have time to perform thorough
medication reviews in their busy practices. However,
agreements on drug choice issues between prescribing
Table 4 Multivariate models of correlates associated with
having at least one unsolved DRP.
p Odds ratio (95% CI)
Model 1
Geriatric depression
scale-15 Score
0.029 1.16 (1.02e1.32)
Model 2
Chronic medication
per patient
0.009 1.19 (1.04e1.37)
Model 3
DRP per patient 0.009 1.37 (1.08e1.74)
Base model: adjusted with baseline variables in Table 1 except
for chronic condition per patient, chronic medication per
patient, and DRP per patient. Model 1: base model þ chronic
condition per patient. Model 2: base model þ chronic medica-
tion per patient. Model 3: base model þ DRP per patient.
CI Z confidence interval; DRP Z drug-related problem.
112 D.-C. Chan et al.physicians and the MSRC team were not high. Prescribers
sometimes felt offended when we proposed that some drugs
might not have sound indications or that some necessary
drugs were not prescribed. In fact, half of the unsolved DRPs
arose from these two categories in our study.
Previous research showed that structured medication
review had positive impacts on the quality of the
prescribing process,17e19 but only limited impacts on clin-
ical outcomes.17,18,20 We found benefits on decreasing the
number of prescriptions and improving the self-reported
health status, but negative impacts on the functional
status. However, the 0.5-point decline in both Nagi index
(maximum 28) and IADL (maximum 32) summary scores was
probably not clinically significant. In the Chinese Longitu-
dinal Healthy Longevity Survey, a decline of about 1 point in
IADL measures (on a 12-point scale) over a 2-year period
was also observed.21 Our finding might be attributable to
a normal, aging-related functional decline in 6 months.
Another plausible explanation was that many uncontrolled
clinical factors such as disease progression might have had
a larger impact on functional status than on improved
prescription quality.
In other countries, medication review is often performed
by clinical pharmacists.17 Prior to 1997, physicians could
prescribe and dispense medications without the assistance of
pharmacists in Taiwan.22 Even after the separation of the two
professions, meaningful outpatient clinical pharmacist
services were scarce22 andmainly disease specific.23e25 Their
services often are limited to detection of prescription errors,
adjustment of dosages, and reporting of adverse drug events.
Other aspects of DRPs, especially the appropriateness of
prescriptions, are often not handled owing to the perception
that physicians might felt uncomfortable when being chal-
lenged by pharmacists with their prescribing habits. With the
collaborative efforts of geriatricians and clinical pharmacists,
our MSRC model is timely to improve the prescription quality
for older adults takingmultiplemedications and to coordinate
pharmaceutical care among multiple prescribers. We were
also able to demonstrate that participants highly appreciated
MSRC services, with level of satisfactions being similar to
those found in other pharmacist-led interventions.26,27In the MSRCs, we adopted a comprehensive geriatric
assessment approach. Abundant data allowed us to examine
many correlates of DRPs and the impacts of our interventions
on multiple outcomes simultaneously. However, we also
recognized that our MSRCs were probably too resource
intensive to be replicated in the current format.
Therefore, we proposed the following modifications to
make the model more financially feasible. First, in addition
to medical history and detailed medication information,
cognitive and depression screenings with short question-
naires were recommended28 because these two common
geriatric problems may lead to poor medication adher-
ence.14 We also suggested screening for history of falls
since many medications were associated with a high fall
risk.29 Other standardized geriatric assessment instruments
could be added when time permits. Second, since most
problems could be solved at Week-12 visit, this visit can be
the last visit to record PSR, changes in clinical conditions,
and/or medications, medication adherences, and patient
feedback.
Our study had several important limitations. First, our
sample size was relatively small, and the attrition rate was
relatively high. Those who dropped out from the study
tended to be older with worse physical functions than those
retained in the final analysis. These might explain some of
their reluctance for the follow-up visits. However, the two
groups were similar in their chronic conditions, drug
numbers, DRPs, and other outcomes. Most results from the
remaining 139 participants can still be generalizable to the
entire cohorts. Second, the level of evidence from
a prospective case-series study was not optimal. A future
large-scale randomized control trial will be required for
determining the effectiveness of the MSRC model. Third,
we were unable to control the clustering effects of physi-
cians and other confounders on patient outcomes from our
statistical analysis. Fourth, the PCNE instrument was under
regular revision with the newest version 6.2 being published
in 2009.30 Our results may not be comparable with those
studies that used different versions. Finally, there are
currently no reimbursement system to support the joint
efforts of geriatricians and clinical pharmacists. Future NHI
supports are important to keep the model viable outside of
the research setting.
Conclusions
Medication review and reconciliation become difficult when
multiple physicians prescribe for one patient. In Taiwan,
with under-recognized geriatric medicine, underappreci-
ated clinical pharmacist services, and weak primary care,
the challenges of medication review are even greater. The
MSRC model can serve as a prototype to improve prescrip-
tion quality if sound reimbursements are available.
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